Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.

Oncotarget·2026
Same author

Day case and inpatient elective thyroid lobectomy across England: observational study of variation in practice and safety.

The British journal of surgery·2026
Same author

The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells <i>in vitro</i> and <i>in vivo</i>.

Oncotarget·2025
Same author

GZ17-6.02 interacts with carboplatin and etoposide to kill neuroblastoma cells.

Anti-cancer drugs·2025
Same author

Multi-Objective Design and Optimization of Hardware-Friendly Grid-Based Sparse MIMO Arrays.

Sensors (Basel, Switzerland)·2024
Same author

Retraction Notice to: Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant Glioma.

Molecular therapy : the journal of the American Society of Gene Therapy·2024

Related Experiment Video

Updated: May 2, 2026

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
07:39

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Published on: June 16, 2018

9.1K

Met in lung cancer.

Paul Dent1

  • 1Department of Biochemistry; Massey Cancer Center; Virginia Commonwealth University; Richmond, VA USA.

Cancer Biology & Therapy
|March 13, 2014
PubMed
Summary

Targeted therapy for non-small cell lung cancer (NSCLC) using epidermal growth factor receptor (EGFR) inhibitors like gefitinib shows initial success. However, acquired resistance, sometimes independent of EGFR mutations, necessitates exploring alternative resistance mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Receptor tyrosine kinases are crucial in cancer cell biology.
  • Activating mutations in epidermal growth factor receptor (EGFR) drive 10% of non-small cell lung cancer (NSCLC) cases.
  • EGFR-addicted NSCLC cells respond to EGFR inhibitors like gefitinib.

Purpose of the Study:

  • To investigate mechanisms of acquired resistance to EGFR inhibitors in NSCLC.
  • To understand why some NSCLC patients develop resistance to gefitinib independent of EGFR mutations.

Main Methods:

  • Analysis of EGFR mutations in NSCLC patients.
  • Clinical observation of tumor response and resistance to gefitinib and afatinib.
  • Identification of resistance mechanisms beyond secondary EGFR mutations.
Keywords:
ALKEGFRc-Metcombination therapymTORtargeted cancer therapy

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K

Related Experiment Videos

Last Updated: May 2, 2026

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
07:39

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Published on: June 16, 2018

9.1K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K

Main Results:

  • Gefitinib treatment leads to initial tumor regression in EGFR-mutated NSCLC.
  • Acquired resistance develops in 12-18 months, often due to a second EGFR mutation.
  • A subset of patients develops gefitinib resistance without secondary EGFR mutations.

Conclusions:

  • While secondary EGFR mutations explain some gefitinib resistance, other mechanisms are involved.
  • Further research is needed to elucidate non-EGFR-mediated resistance pathways.
  • Understanding diverse resistance mechanisms is critical for improving NSCLC treatment strategies.